Indian pharmaceutical firm Zydus Cadila revealed that it has received the final approval from the US Food and Drug Administration to market its anti-diabetic drug, Pioglitazone HCI, in the American market.
Zydus announced that it has received approval to market Pioglitazone HCI tablets in 15 mg, 30 mg and 45 mg strengths. The company added that sales for Pioglitazone HCI tablets was estimated at $2 billion in 2012, according to data from IMS.
Advertisement
The company has so far filed over 170 Abbreviated New Drug Applications (ANDA) since 2003-04 and has so far received 75 approvals, including for the sale of oral tablets of Ultracet.
Source: Medindia
Diabetes Diet Plan
Diet plays a significant role in controlling diabetes. Most cases of diabetes are preventable with healthy lifestyle changes.
Advertisement
 Diabetes and ExerciseRegular exercise especially in type II diabetes not only helps reduce the sugar but also reduces the demand for medication by 20% and helps you stay healthy. | Advertisement
|
Advertisement
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
